Enhanced ADCC Activity of a C-Terminal Lysine Variant of an IgG<sub>1</sub> Antibody Driven by N-Linked MAN5 Glycan Using a Reporter Gene Assay.

Antibodies (Basel) · 2025 · PMC12550915 · PMID 41133683

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

The differences observed between B2 and CPB-treated B2 were minor (less than 6%), though marginally significant, likely due to assay variability.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Enhanced ADCC Activity of a C-Terminal Lysine Variant of an IgG&lt;sub&gt;1&lt;/sub&gt; Antibody Driven by N-Linked MAN5 Glycan Using a Reporter Gene Assay.

The sentences

Enhanced ADCC Activity of a C-Terminal Lysine Variant of an IgG<sub>1</sub> Antibody Driven by N-Linked MAN5 Glycan Using a Reporter Gene Assay.